Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-ICOS ligand Antibody (1W488) is a Mouse antibody targeting ICOS ligand. Anti-ICOS ligand Antibody (1W488) can be used in FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 μL | $68 | 7-10 days | |
100 μL | $199 | 7-10 days |
Description | Anti-ICOS ligand Antibody (1W488) is a Mouse antibody targeting ICOS ligand. Anti-ICOS ligand Antibody (1W488) can be used in FCM. |
Alias | LICOS, inducible T-cell co-stimulator ligand, ICOSLG, ICOS-L, ICOSL, ICOS ligand, GL50, CD275, B7RP-1, B7RP1, B7-h2, B7H2 |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 1W488 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human ICOSLG(CD275) expression on RPMI8226 cells. Cells were stained with purified anti-Human ICOSLG(CD275), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | FCM: 1:25-1:100 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human ICOS Ligand / B7-H2 (rh ICOS Ligand / B7-H2; TMPY-01672; NP_056074.1; Met1-Ser258). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Inducible co-stimulator ligand (ICOSL), also known as B7-H2, is a member of the B7 family of co-stimulatory molecules related to B7-1 and B7-2. It is a transmembrane glycoprotein with extracellular IgV and IgC domains and binds to ICOS on activated T cells, thus delivers a positive costimulatory signal for optimal T cell function. The structural features of ICOSL are crucial for its costimulatory function. The present study shows that ICOSL displays a marked oligomerization potential, resembling more like B7-1 than B7-2. B7-H2-dependent signaling may play an active role in a proliferative response rather than in cytokine and chemokine production. The CD28/B7 and ICOS/B7-H2 pathways are both critical for costimulating T cell immune responses. Deficiency in either pathway results in defective T cell activation, cytokine production, and germinal center formation.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Others Formats | APC/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human ICOS Ligand / B7-H2 Protein (TMPY-01672) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.